- /
- Supported exchanges
- / F
- / CSJA.F
CSL LTD SPON.ADR 2 (CSJA F) stock market data APIs
CSL LTD SPON.ADR 2 Financial Data Overview
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get CSL LTD SPON.ADR 2 data using free add-ons & libraries
Get CSL LTD SPON.ADR 2 Fundamental Data
CSL LTD SPON.ADR 2 Fundamental data includes:
- Net Revenue: 15 558 M
- EBITDA: 4 909 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-10
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSL LTD SPON.ADR 2 News
New
CSL (ASX:CSL) Valuation Check After Vanguard Stake Increase And Upcoming Half Year Results
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Vanguard Group’s decision to lift its stake in CSL (ASX...
Does Rising Institutional Influence Amid Seqirus Uncertainty Change The Bull Case For CSL (ASX:CSL)?
Vanguard has recently lifted its voting power in CSL to 6% ahead of the company’s February half-year results and interim dividend update, while Deutsche Bank has been appointed successor depositary ...
Is CSL (ASX:CSL) Now Attractive After A 34% One Year Share Price Decline?
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. If you are wondering whethe...
CSLLY or TECH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Techne (TECH). But which of these two stocks offers value investors a be...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.